Source: Pharmacy Times articles
The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.
Read More
Recent Content
- Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
- Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
- Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
- Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
- (no title)
- The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
- (no title)
- Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
- (no title)
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis